Antimicrobials reserved for specific human infections

This procedure allows for an objection to be raised against the designation of specific antimicrobials reserved for treating human infections. It ensures that such designations are appropriate and do not negatively impact public health strategies.

This affects the pharmaceutical industry and healthcare providers. It ensures that critical medicines remain available for human use, safeguarding public health and treatment options.